Dexcom stock gains as 10% revenue growth holds

Published on 09/14/2026 at 21:28 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Dexcom stock is trading at a market cap of USD 31.33 billion on September 14, 2026. TradingView says the company reaffirmed 10%+ revenue growth guidance and highlighted CONNECT trial results.

Fotorealistischer CGM-Sensor-Patch am Arm, klinisches Umfeld, Medizintechnik — Dexcom Inc. zeigt fotorealistischen CGM-Sensor am Unterarm für Anleger mit ISIN US2521311074 Medizintechnik, Illustration mit AI erstellt.

Dexcom Inc. stock (ISIN US2521311074) is supported by a market cap of USD 31.33 billion on September 14, 2026, while the stock portal snapshot shows a 52-week range of USD 54.11 to USD 92.59.

CONNECT and guidance

As TradingView reported on September 14, 2026, DexCom, Inc. said strong CONNECT trial results for its 15-day sensor with AI features support expected expanded coverage by mid-2027 and it reaffirmed 10%+ revenue growth guidance. The same report said the company also added Glenn S. Boehnlein to its board to bolster finance and M&A expertise.

That leaves investors with two dated checkpoints: the trial update points to a mid-2027 coverage path, and the guidance call still centers on 10%+ revenue growth. The stock moves on execution more than on theme.

Price and range

StockAnalysis shows DexCom at USD 82.83 to USD 85.82 intraday on September 14, 2026, with volume of 2,547,398 shares, market cap of USD 31.33 billion and a 52-week range of USD 54.11 to USD 92.59. The close sits well above the 52-week low and below the 52-week high.

What matters now

For investors, the key number is the 10%+ revenue growth guide, because it sits next to a 15-day sensor update that could broaden coverage by mid-2027. If that timeline holds, the current valuation leaves little room for weak follow-through.